Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recommendations about add-on reimbursement for medical devices in France in October 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in October 2023. Twelve recommendations were published in relation to the registration of medical devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, e-health, endocrine, gastrointestinal, neurology and neurosurgery, neuromodulation, and orthopedic devices, as well as medical aids.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Some examples of the recommendations regarding applications for registration are provided below:

  • Implantable cardiac pacemaker with atrio-biventricular stimulation for “triple chamber” resynchronization AMVIA SKY HF-T by Biotronik (sufficient actual benefit; level V of clinical added value compared to EDORA 8 HF-T);
  • MYLIFE CAMAPS FX (MYLIFE YPSOPUMP insulin pump with CAMAPS FX app with FREESTYLE LIBRE 3 sensor) by Ypsomed (sufficient actual benefit; level III of clinical added value compared to other systems (called open loop) composed of an external insulin pump and a sensor for measuring the interstitial glucose level, operating independently);
  • Non-rechargeable neuromodulator of the sacral root neuromodulation system INTERSTIM X by Medtronic (sufficient actual benefit; level IV of clinical added value compared to INTERSTIM II, a non-rechargeable sacral root system);
  • Chitosan tube intended to protect direct suturing of severed peripheral nerves REAXON DIRECT by KeriMedical (insufficient actual benefit);
  • Microwave soft tissue ablation probe NEUWAVE by Johnson & Johnson (sufficient actual benefit; level V of clinical added value compared to radiofrequency ablation).

Also, recommendations were made in relation to other cardiovascular devices, orthopedic devices, and medical aids.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.